Market Cap 216.37M
Revenue (ttm) 144.29M
Net Income (ttm) -13.58M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -9.41%
Debt to Equity Ratio 7.22
Volume 608,490
Avg Vol 1,505,942
Day's Range N/A - N/A
Shares Out 183.36M
Stochastic %K 37%
Beta 1.25
Analysts Strong Sell
Price Target $4.50

Company Profile

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed na...

Industry: Biotechnology
Sector: Healthcare
Phone: (858) 251-4400
Address:
100 Regency Forest Drive, Suite 300, Cary, United States
EMINENZ
EMINENZ Feb. 22 at 3:03 PM
$HRTX thursday earnings. Fingers crossed we see a nice bouce.
1 · Reply
BillionerOfKing
BillionerOfKing Feb. 21 at 10:02 PM
$HRTX Current Stock Price: $1.19 Contracts to trade: $1.0 HRTX Mar 20 2026 Call Entry: $0.15 Exit: $0.29 ROI: 93% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
BullMaven
BullMaven Feb. 21 at 7:50 PM
$HRTX keep loading at this level.
0 · Reply
keypatience
keypatience Feb. 20 at 5:08 PM
$HRTX VAN transition (easier use) + J-code (cleaner reimbursement) are the kind of fixes that can keep demand climbing. NOPAIN Act traction is also important. Pretty straightforward setup for improving growth plus operating leverage in my opinion. I remain extremely bullish here.
1 · Reply
ChartKev21
ChartKev21 Feb. 20 at 4:26 PM
$HRTX Heron Therapeutics markets pain management therapies. Revenue growth depends on adoption. Pipeline execution matters.
0 · Reply
Shooter40
Shooter40 Feb. 20 at 1:52 PM
$HRTX lets put things in perspective here. The last data point, the early release of Q4 revenues, was terrific. CC has delivered on most everything he has said he would do. They are not great communicators, but they have turned the ship and it is sailing in the right direction. We have a lot of tailwinds now with the reimbursement changes and vial adapter. We need to chill out and let’s give CC the next two quarters to prove he has created a growth engine now. Its crazy to skewer him right now when he has done almost exactly what he set out to do several years ago. I know we are all frustrated with the enormous time span we have endured, but its not his fault, its ours.
3 · Reply
keypatience
keypatience Feb. 19 at 11:42 PM
$HRTX Extremely bullish here
1 · Reply
Braddog
Braddog Feb. 19 at 7:26 PM
$HRTX So I just can’t help say how I feel, because in my lifetime of experience something bad is going to happen in the world. Does anyone think there won’t be another crisis? Heron should be sold and sold soon. Strong recession?…. National debt issue? Another war?… Taiwan, China will shut down our internet and way worse. Global pandemic? That could never happen! The longer CC and BOD holds out for the dream of $4.5 or higher THE GREATER THE CHANCE ALOT OF US LOSE IT ALL!!!!!!! Heron is a failed investment. Up to this point. They had 5 drugs now down to 3. Now the cash cow, the life line, Cinvanti is probably struggling. CC needs to communicate strong profitability on Feb 27. If not the risk reward may not be there anymore. He had talked about profitability along like 2 years ago. SHOW ME THE Fing MONEY or SELL TO SOMEONE THAT CAN DELIVER! Herons drugs need to be in the hands of big pharma Heron is struggling.
3 · Reply
Braddog
Braddog Feb. 19 at 2:52 PM
$HRTX Heron is so heavily shorted that we will probably have meaningful sales growth and not have much appreciation in the PPS! Until the shorts decide to leave……. The longs are F&cked! And god help us if Heron has bad news on Cinvanti!
2 · Reply
jacksonjohn750
jacksonjohn750 Feb. 19 at 12:44 PM
$HRTX do we get a SA pump today?
0 · Reply
Latest News on HRTX
Heron: Near The Bottom Of A Trading Range Despite Positives

Feb 18, 2026, 10:28 AM EST - 5 days ago

Heron: Near The Bottom Of A Trading Range Despite Positives


Heron Therapeutics, Inc. (HRTX) Q1 2025 Earnings Call Transcript

May 6, 2025, 11:38 AM EDT - 10 months ago

Heron Therapeutics, Inc. (HRTX) Q1 2025 Earnings Call Transcript


U.S. District Court Upholds Validity of CINVANTI® Patents

Dec 3, 2024, 4:36 PM EST - 1 year ago

U.S. District Court Upholds Validity of CINVANTI® Patents


Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain

Apr 16, 2024, 4:24 PM EDT - 2 years ago

Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain


Heron Therapeutics, Inc. (HRTX) Q4 2023 Earnings Call Transcript

Mar 12, 2024, 10:35 PM EDT - 2 years ago

Heron Therapeutics, Inc. (HRTX) Q4 2023 Earnings Call Transcript


Heron Therapeutics Is Out Of Survival Mode

Feb 17, 2024, 1:54 AM EST - 2 years ago

Heron Therapeutics Is Out Of Survival Mode


EMINENZ
EMINENZ Feb. 22 at 3:03 PM
$HRTX thursday earnings. Fingers crossed we see a nice bouce.
1 · Reply
BillionerOfKing
BillionerOfKing Feb. 21 at 10:02 PM
$HRTX Current Stock Price: $1.19 Contracts to trade: $1.0 HRTX Mar 20 2026 Call Entry: $0.15 Exit: $0.29 ROI: 93% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
BullMaven
BullMaven Feb. 21 at 7:50 PM
$HRTX keep loading at this level.
0 · Reply
keypatience
keypatience Feb. 20 at 5:08 PM
$HRTX VAN transition (easier use) + J-code (cleaner reimbursement) are the kind of fixes that can keep demand climbing. NOPAIN Act traction is also important. Pretty straightforward setup for improving growth plus operating leverage in my opinion. I remain extremely bullish here.
1 · Reply
ChartKev21
ChartKev21 Feb. 20 at 4:26 PM
$HRTX Heron Therapeutics markets pain management therapies. Revenue growth depends on adoption. Pipeline execution matters.
0 · Reply
Shooter40
Shooter40 Feb. 20 at 1:52 PM
$HRTX lets put things in perspective here. The last data point, the early release of Q4 revenues, was terrific. CC has delivered on most everything he has said he would do. They are not great communicators, but they have turned the ship and it is sailing in the right direction. We have a lot of tailwinds now with the reimbursement changes and vial adapter. We need to chill out and let’s give CC the next two quarters to prove he has created a growth engine now. Its crazy to skewer him right now when he has done almost exactly what he set out to do several years ago. I know we are all frustrated with the enormous time span we have endured, but its not his fault, its ours.
3 · Reply
keypatience
keypatience Feb. 19 at 11:42 PM
$HRTX Extremely bullish here
1 · Reply
Braddog
Braddog Feb. 19 at 7:26 PM
$HRTX So I just can’t help say how I feel, because in my lifetime of experience something bad is going to happen in the world. Does anyone think there won’t be another crisis? Heron should be sold and sold soon. Strong recession?…. National debt issue? Another war?… Taiwan, China will shut down our internet and way worse. Global pandemic? That could never happen! The longer CC and BOD holds out for the dream of $4.5 or higher THE GREATER THE CHANCE ALOT OF US LOSE IT ALL!!!!!!! Heron is a failed investment. Up to this point. They had 5 drugs now down to 3. Now the cash cow, the life line, Cinvanti is probably struggling. CC needs to communicate strong profitability on Feb 27. If not the risk reward may not be there anymore. He had talked about profitability along like 2 years ago. SHOW ME THE Fing MONEY or SELL TO SOMEONE THAT CAN DELIVER! Herons drugs need to be in the hands of big pharma Heron is struggling.
3 · Reply
Braddog
Braddog Feb. 19 at 2:52 PM
$HRTX Heron is so heavily shorted that we will probably have meaningful sales growth and not have much appreciation in the PPS! Until the shorts decide to leave……. The longs are F&cked! And god help us if Heron has bad news on Cinvanti!
2 · Reply
jacksonjohn750
jacksonjohn750 Feb. 19 at 12:44 PM
$HRTX do we get a SA pump today?
0 · Reply
Biotech_Beast
Biotech_Beast Feb. 19 at 1:20 AM
$HRTX (I'm long) Zynrelef has had a breakout quarter with Q4'25 preliminary numbers, and Aponvie continues to perform. I take a look at the name. https://seekingalpha.com/article/4871440-heron-near-the-bottom-of-a-trading-range-despite-positives
0 · Reply
AlwaysMoneySZN
AlwaysMoneySZN Feb. 18 at 3:31 PM
$HRTX more volume please
0 · Reply
BullMaven
BullMaven Feb. 18 at 3:29 PM
0 · Reply
jacksonjohn750
jacksonjohn750 Feb. 18 at 12:53 PM
$HRTX we need more seeking alpha pumps
0 · Reply
MidnightPivot
MidnightPivot Feb. 18 at 7:39 AM
$HRTX Heron Therapeutics commercializes acute care and oncology supportive care drugs, facing commercial execution challenges and debt overhang [citation:historical].
1 · Reply
meistermell
meistermell Feb. 17 at 7:35 PM
1 · Reply
milans100
milans100 Feb. 17 at 7:30 PM
$HRTX @Braddog moves the needle :-)
1 · Reply
AlwaysMoneySZN
AlwaysMoneySZN Feb. 17 at 6:48 PM
$HRTX would love to see some real volume
0 · Reply
Braddog
Braddog Feb. 17 at 2:18 PM
$HRTX I wonder if the Bloomberg sales numbers will cause some buying?
0 · Reply
jacksonjohn750
jacksonjohn750 Feb. 17 at 1:32 PM
$HRTX would be nice to see a pop today and not have it fade
0 · Reply
Braddog
Braddog Feb. 16 at 3:01 PM
$HRTX Maybe Heron generate $190M in rev this year. $95M Cinvanti $65M Zyn $30M Aponvie
1 · Reply
Shooter40
Shooter40 Feb. 16 at 11:43 AM
$HRTX january was a terrible month for weather. Snow, ice, power outages…….imagine what better weather may result in!
0 · Reply